-+ 0.00%
-+ 0.00%
-+ 0.00%
Viking Therapeutics (VKTX) Stock Trades At A Premium To Book Value
Share
Listen to the news

Viking Therapeutics has ridden a powerful multi year share price run, yet the recent pullback and heavier funding needs now put a sharper spotlight on what investors are actually paying for on its balance sheet. With the stock reacting to fresh obesity drug data and capital raises, the open question is how today’s market value lines up against Viking Therapeutics' book value compared with the wider biotech industry.

  • Over the past 5 years, Viking Therapeutics has delivered a very large share price gain of about 3.6x, which raises the stakes on whether that move is grounded in the company’s underlying net assets.
  • Progress with obesity candidate VK2735 and the roughly US$960m of recent equity and convertible funding can reshape both future cash needs and the book value base that investors are using as a reference point.
  • There is a second opinion on Viking Therapeutics worth weighing. See what analysts think Viking Therapeutics's shares could be worth.

The stock's next move may depend on whether Viking Therapeutics' current share price still lines up sensibly with its book value when set against the industry average.

If you want to test the same book value question beyond Viking Therapeutics, apply the same rule to a broader set of biotech valuations with 35 high quality undervalued stocks

Does Viking Therapeutics Look Pricey on Book Value?

P/B fits Viking Therapeutics because it is still in a loss making phase and investors are effectively paying for its research pipeline and cash on the balance sheet. The stock trades on a P/B of about 5.6x, well above the broader biotech sector on roughly 1.7x and still below the 7.3x level seen across closer peers.

Because the ratio is far higher than the industry average, the shares screen as overvalued on this simple balance sheet lens, even after the recent pullback around VK2735 updates. Despite the latest Phase 3 progress and fresh obesity data lifting interest in Viking Therapeutics, the current P/B still implies a rich price tag relative to many other biotechs that the market values at lower multiples of book value. Explore the numbers behind Viking Therapeutics's P/B valuation.

NasdaqCM:VKTX P/B Ratio as at Nov 2026
NasdaqCM:VKTX P/B Ratio as at Nov 2026

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Viking Therapeutics' P/B puzzle leaves off by spelling out what kind of future on growth, profitability and earnings would need to play out for the shares to look materially higher or lower than today’s valuation on the Community page. Rather than leaning on a single multiple or model output, each scenario lays out the assumptions behind its view of value so you can compare those expectations with actual results as they are reported.

One of the top narratives on Viking Therapeutics: 79% undervalued

This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.

"VK2735’s maintenance data, with roughly 16 to 19% weight loss over 21 weeks and high proportions of patients reaching double digit weight loss, opens the door to differentiated labeling and pricing power if long term outcomes align…"

Discover why this Narrative puts Viking Therapeutics at 79% undervalued.

The valuation still leaves a crucial issue hanging for Viking Therapeutics

Price tags and book value only tell part of the story for Viking Therapeutics, because separate checks have flagged specific risks that can shift how you weigh everything you just read. Take a closer look at 3 warning signs (1 major) before settling on a valuation.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending